A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Samalizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Alexion Pharmaceuticals
- 27 Oct 2017 Status changed from suspended to discontinued.
- 03 Aug 2017 Status changed from recruiting to suspended.
- 12 Dec 2016 New trial record